tbuckley/cabot-search huggingface dataset:
Arrhythmogenic Cardiomyopathy
Authors: Domenico Corrado, Cristina Basso, Daniel P. Judge
Journal: Circulation Research (2017)

Arrhythmogenic cardiomyopathy is an inherited heart muscle disorder, predisposing to sudden cardiac death, particularly in young patients and athletes. Pathological features include loss of myocytes and fibrofatty replacement of right ventricular myocardium; biventricular involvement is often observed. It is a cell-to-cell junction cardiomyopathy, typically caused by genetically determined abnormalities of cardiac desmosomes, which leads to detachment of myocytes and alteration of intracellular signal transduction. The diagnosis of arrhythmogenic cardiomyopathy does not rely on a single gold standard test but is achieved using a scoring system, which encompasses familial and genetic factors, ECG abnormalities, arrhythmias, and structural/functional ventricular alterations. The main goal of treatment is the prevention of sudden cardiac death. Implantable cardioverter defibrillator is the only proven lifesaving therapy; however, it is associated with significant morbidity because of device-related complications and inappropriate implantable cardioverter defibrillator interventions. Selection of patients who are the best candidates for implantable cardioverter defibrillator implantation is one of the most challenging issues in the clinical management.
NORWAY
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Integrated PET/MRI With 68Ga-DOTATATE and 18F-FDG in Pheochromocytomas and Paragangliomas
Authors: Si Xu, Yu Pan, Jinxin Zhou, Huijun Ju, Yifan Zhang
Journal: Clinical Nuclear Medicine (2022)

Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors with metastatic potential. Both 68Ga-DOTATATE and 18F-FDG PET/CT scans have been demonstrated to have important roles in imaging PPGLs, but less is known about the performance of PET/MRI for PPGLs. The study is aimed to investigate whether diffusion-weighted imaging-MRI (DWI-MRI) has an added value to PET imaging in the identification of PPGL lesions by means of integrated PET/MRI.Eleven patients who underwent both 18F-FDG and 68Ga-DOTATATE PET/MRI within 2 weeks were retrospectively included in the study. A total of 56 PPGL lesions were analyzed, and lesion-based detection rates of 68Ga-DOTATATE PET, 18F-FDG PET, DWI-MRI, and PET/MRI were calculated and compared, respectively.68Ga-DOTATATE PET was superior to 18F-FDG PET and DWI-MRI in imaging PPGLs with a lesion-based detection rate of 96.4% (54/56) (95% confidence interval [CI], 87.7%-99.6%), 85.7% (48/56) (95% CI, 76.3%-95.2%), and 89.3% (50/56) (95% CI, 80.9%-97.6%), respectively. PET/MRI with DWI could improve the detection rate of 68Ga-DOTATATE and 18F-FDG PET alone up to 100% in metastatic PPGLs. Lesions of PPGL demonstrated markedly higher tracer uptake in 68Ga-DOTATATE PET than in 18F-FDG PET (P = 0.009 for primary lesion, P = 0.033 for metastases).68Ga-DOTATATE PET showed a higher detection rate than 18F-FDG for PPGLs. In integrated PET/MRI, MRI had an added value to 18F-FDG PET but not much to 68Ga-DOTATATAE PET in identifying PPGL lesions.
2nd European Symposium on Lyme Borreliosis. A NATO advanced research workshop. United Kingdom, 19-20 May 1993. Abstracts.
Authors: John Axford, Allen Steere, Klaus Hansen, Susan Henderson, Lyme Borreliosis, St George's Hospiial, John London, Martin Brown, Sue O'connellt, E Rees, S Curtin, A Leanordt, T Pennington, C Young, S Reddy, M Gibson, T Omran, J Rawlingst, C Davidt
Journal: Annals of the Rheumatic Diseases (1993)

Confirmation of serological reactivity can be achieved by immunoblotting.As the disease progresses antibodies are produced against a range of borrelial proteins, both specific and non-specific.The interpretation of immunoblot patterns is an area of controversy with many different schemes available.Some studies have reported poor specificity of immunoblotting,5 whereas others maintain that the technique is highly specific.'These discrepancies largely result from differing methods used for interpreta- tion.We prefer to use a weighted system for interpretation, with greater value being attached to bands considered to be specific, while other bands are considered less important.7Problems with serodiagnosis arise during
Sleep-disordered Breathing in Pregnancy and after Delivery: Associations with Cardiometabolic Health
Authors: Francesca L. Facco, Susan Redline, Shannon M. Hunter, Phyllis C. Zee, William A. Grobman, Robert M. Silver, Judette M. Louis, Grace W. Pien, Brian Mercer, Judith H. Chung, C. Noel Bairey Merz, David M. Haas, Chia-Ling Nhan-Chang, Hyagriv N. Simhan, Frank P. Schubert, Samuel Parry, Uma Reddy, George R. Saade, Matthew K. Hoffman, Lisa D. Levine, Ronald J. Wapner, Janet M. Catov, Corette B. Parker
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

Knowledge gaps exist regarding health implications of sleep-disordered breathing (SDB) identified in pregnancy and/or after delivery.
KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications
Journal: Clinical and Molecular Hepatology (2020)

Background and aimsPatients with decompensated cirrhosis with complications have a very poor prognosis and require careful management.Varices are common complications in patients with cirrhosis.Although the prognosis of variceal bleeding has improved with recent advances in diagnosis and treatment, the mortality rate remains 12-22%.Hepatic encephalopathy (HE) is known to occur in 10-14% of patients with cirrhosis and 16-21% of patients with decompensated cirrhosis.More than 20% of cirrhotic patients who visit emergency rooms in Korea present with HE.Therefore, cirrhosis is a serious disease in Korea and requires specific Korean guidelines for diagnosis, treatment, and prevention.In 2005, the Korean Association for the Study of the Liver (KASL) enacted a clinical practice guideline (CPG) for the treatment of cirrhosis complications including ascites, hepatorenal syndrome, varices, and HE.In 2011, the guidelines for the treatment of cirrhosis were revised to integrate antifibrotic treatment and update the diagnosis and treatment advice for variceal bleeding, cirrhotic ascites, and HE.In 2017, the CPG for liver cirrhosis was revised for ascites and related complications.At this time, KASL is revising the CPG for liver cirrhosis to address varices and HE following ascites and related complications.To date, many studies have addressed the prevention and treatment of gastroesophageal variceal bleeding and HE, and many guidelines have been based on those studies, but most of them contain foreign data that are difficult to apply to Korean KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complicationsThe Korean Association for the Study of the Liver (KASL)
MORBIDITY OF BRITISH WORKERS
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Department of Public Health.
Journal: JAMA (1898)

Washington, Dec. 7, 1897. HonorableFrank S. Gardner, Secretary New York Board of Trade and Transportation, New York City. <h3>Dear Sir:</h3> —Having seen a letter addressed to yourself by Warren E. Anderson, dated Pensacola, Florida, Nov. 24, 1897, and published in theJournal of the American Medical Associationin which this gentleman undertakes a serial criticism of "The Efficiency of the Marine-Hospital Service in the conduct of Federal Health Affairs," and which he states is made "without malice toward any one or animus of a personal character whatever," I take the liberty of stating to you that there appeared before a board of examiners of the Marine-Hospital Service in June, 1883, one Warren E. Anderson, a native of Marianna, Florida, and a graduate of the Medical College of Alabama. It may be interesting for you to inquire whether the gentleman who writes to you upon the character and abilities of
CARDINAL FACTORS IN PULMONARY EDEMA
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Errata
Journal: BMJ (1908)

Wtttt, toes in b.zhregs -m QuerIes, emsiver, sad _.ommnmcggons reato So ab* b0 which pSe dePartms of the BRmsITS MDIaL JOURNAL Ws deoed UW be found under their respecive headinge.Qvuaxus.1WWs ld
Nonconsequentialist decisions
Authors: Jonathan Baron
Journal: Behavioral and Brain Sciences (1994)

Abstract According to a simple form of consequentialism, we should base decisions on our judgments about their consequences for achieving our goals. Our goals give us reason to endorse consequentialism as a standard of decision making. Alternative standards invariably lead to consequences that are less good in this sense. Yet some people knowingly follow decision rules that violate consequentialism. For example, they prefer harmful omissions to less harmful acts, they favor the status quo over alternatives they would otherwise judge to be belter, they provide third-party compensation on the basis of the cause of an injury rather than the benefit from the compensation, they ignore deterrent effects in decisions about punishment, and they resist coercive reforms they judge to be beneficial. I suggest that nonconsequentialist principles arise from overgeneralizing rules that are consistent with consequentialism in a limited set of cases. Commitment to such rules is detached from their original purposes. The existence of such nonconsequentialist decision biases has implications for philosophical and experimental methodology, the relation between psychology and public policy, and education.
ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery,⁎Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management…
Authors: Alan T. Hirsch, Ziv J. Haskal, Norman R. Hertzer, Curtis W. Bakal, Mark A. Creager, Jonathan L. Halperin, Loren F. Hiratzka, William R.C. Murphy, Jeffrey W. Olin, Jules B. Puschett, Kenneth A. Rosenfield, David Sacks, James C. Stanley, Lloyd M. Taylor, Christopher J. White, John White, Rodney A. White, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Raymond J. Gibbons, Jonathan L. Halperin, Loren F. Hiratzka, Sharon A. Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel
Journal: Journal of the American College of Cardiology (2006)
Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions
Authors: Gilles S. van Tienderen, Ling Li, Laura Broutier, Yoshimasa Saito, Patricia Inacio, Meritxell Huch, Florin M. Selaru, Luc J.W. van der Laan, Monique M.A. Verstegen
Journal: Cancer Cell (2022)
13. Children and Adolescents: <i>Standards of Medical Care in Diabetes−2020</i>
Journal: Diabetes Care (2019)

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Authors: Paul T Heath, Eva P Galiza, David N Baxter, Marta Boffito, Duncan Browne, Fiona Burns, David R Chadwick, Rebecca Clark, Catherine Cosgrove, James Galloway, Anna L Goodman, Amardeep Heer, Andrew Higham, Shalini Iyengar, Arham Jamal, Christopher Jeanes, Philip A Kalra, Christina Kyriakidou, Daniel F McAuley, Agnieszka Meyrick, Angela M Minassian, Jane Minton, Patrick Moore, Imrozia Munsoor, Helen Nicholls, Orod Osanlou, Jonathan Packham, Carol H Pretswell, Alberto San Francisco Ramos, Dinesh Saralaya, Ray P Sheridan, Richard Smith, Roy L Soiza, Pauline A Swift, Emma C Thomson, Jeremy Turner, Marianne E Viljoen, Gary Albert, Iksung Cho, Filip Dubovsky, Greg Glenn, Joy Rivers, Andreana Robertson, Kathy Smith, Seth Toback
Journal: New England Journal of Medicine (2021)

Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the vaccine was safe and associated with a robust immune response in healthy adult participants. Additional data were needed regarding the efficacy, immunogenicity, and safety of this vaccine in a larger population.In this phase 3, randomized, observer-blinded, placebo-controlled trial conducted at 33 sites in the United Kingdom, we assigned adults between the ages of 18 and 84 years in a 1:1 ratio to receive two intramuscular 5-μg doses of NVX-CoV2373 or placebo administered 21 days apart. The primary efficacy end point was virologically confirmed mild, moderate, or severe SARS-CoV-2 infection with an onset at least 7 days after the second injection in participants who were serologically negative at baseline.A total of 15,187 participants underwent randomization, and 14,039 were included in the per-protocol efficacy population. Of the participants, 27.9% were 65 years of age or older, and 44.6% had coexisting illnesses. Infections were reported in 10 participants in the vaccine group and in 96 in the placebo group, with a symptom onset of at least 7 days after the second injection, for a vaccine efficacy of 89.7% (95% confidence interval [CI], 80.2 to 94.6). No hospitalizations or deaths were reported among the 10 cases in the vaccine group. Five cases of severe infection were reported, all of which were in the placebo group. A post hoc analysis showed an efficacy of 86.3% (95% CI, 71.3 to 93.5) against the B.1.1.7 (or alpha) variant and 96.4% (95% CI, 73.8 to 99.5) against non-B.1.1.7 variants. Reactogenicity was generally mild and transient. The incidence of serious adverse events was low and similar in the two groups.A two-dose regimen of the NVX-CoV2373 vaccine administered to adult participants conferred 89.7% protection against SARS-CoV-2 infection and showed high efficacy against the B.1.1.7 variant. (Funded by Novavax; EudraCT number, 2020-004123-16.).
Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity
Authors: Catherine Riou, Roanne Keeton, Thandeka Moyo-Gwete, Tandile Hermanus, Prudence Kgagudi, Richard Baguma, Ziyaad Valley-Omar, Mikhail Smith, Houriiyah Tegally, Deelan Doolabh, Arash Iranzadeh, Lynn Tyers, Hygon Mutavhatsindi, Marius B. Tincho, Ntombi Benede, Gert Marais, Lionel R. Chinhoyi, Mathilda Mennen, Sango Skelem, Elsa du Bruyn, Cari Stek, Tulio de Oliveira, Carolyn Williamson, Penny L. Moore, Robert J. Wilkinson, Ntobeko A. B. Ntusi, Wendy A. Burgers
Journal: Science Translational Medicine (2022)

SARS-CoV-2 variants that escape neutralization and potentially affect vaccine efficacy have emerged. T cell responses play a role in protection from reinfection and severe disease, but the potential for spike mutations to affect T cell immunity is incompletely understood. We assessed neutralizing antibody and T cell responses in 44 South African COVID-19 patients either infected with the Beta variant (dominant from November 2020 to May 2021) or infected before its emergence (first wave, Wuhan strain) to provide an overall measure of immune evasion. We show that robust spike-specific CD4 and CD8 T cell responses were detectable in Beta-infected patients, similar to first-wave patients. Using peptides spanning the Beta-mutated regions, we identified CD4 T cell responses targeting the wild-type peptides in 12 of 22 first-wave patients, all of whom failed to recognize corresponding Beta-mutated peptides. However, responses to mutated regions formed only a small proportion (15.7%) of the overall CD4 response, and few patients (3 of 44) mounted CD8 responses that targeted the mutated regions. Among the spike epitopes tested, we identified three epitopes containing the D215, L18, or D80 residues that were specifically recognized by CD4 T cells, and their mutated versions were associated with a loss of response. This study shows that despite loss of recognition of immunogenic CD4 epitopes, CD4 and CD8 T cell responses to Beta are preserved overall. These observations may explain why several vaccines have retained the ability to protect against severe COVID-19 even with substantial loss of neutralizing antibody activity against Beta.
Manuscripts Approved for JNCI, July 1 to August 1, 1965
Journal: JNCI Journal of the National Cancer Institute (1965)

Manuscripts Approved for JNCI, July 1 to August 1, 1965 Get access JNCI: Journal of the National Cancer Institute, Volume 35, Issue 3, September 1965, Page 580, https://doi.org/10.1093/jnci/35.3.580 Published: 01 September 1965
Radioiodine-Avid Paravertebral Bronchogenic Cyst Mimicking Neurofibroma
Authors: Mohammad Reza Shah Mohammadi, Ghazal Norouzi, Elahe Pirayesh
Journal: Clinical Nuclear Medicine (2022)

The whole-body postablation scan of a 38-year-old man, with history of papillary thyroid cancer, revealed a focus of intense 131I accumulation about the lower thoracic vertebrae. SPECT/CT revealing a soft tissue lesion adjacent the T9 to T10 vertebrae, which was reported as neurofibroma on the subsequently performed MRI. However, the lesion was confirmed as a bronchogenic cyst on biopsy. Respecting that unlike neurofibroma, immunohistochemistry studies have confirmed Na-I symporter expression in bronchogenic epithelium; our case highlights that, although rare, paravertebral bronchogenic cysts should be considered in differential diagnosis of radioiodine-avid paravertebral lesions.
Effects of Intensive BP Control in CKD
Authors: Alfred K. Cheung, Mahboob Rahman, David M. Reboussin, Timothy E. Craven, Tom Greene, Paul L. Kimmel, William C. Cushman, Amret T. Hawfield, Karen C. Johnson, Cora E. Lewis, Suzanne Oparil, Michael V. Rocco, Kaycee M. Sink, Paul K. Whelton, Jackson T. Wright, Jan Basile, Srinivasan Beddhu, Udayan Bhatt, Tara I. Chang, Glenn M. Chertow, Michel Chonchol, Barry I. Freedman, William Haley, Joachim H. Ix, Lois A. Katz, Anthony A. Killeen, Vasilios Papademetriou, Ana C. Ricardo, Karen Servilla, Barry Wall, Dawn Wolfgram, Jerry Yee
Journal: Journal of the American Society of Nephrology (2017)

The appropriate target for BP in patients with CKD and hypertension remains uncertain. We report prespecified subgroup analyses of outcomes in participants with baseline CKD in the Systolic Blood Pressure Intervention Trial. We randomly assigned participants to a systolic BP target of &lt;120 mm Hg (intensive group; n =1330) or &lt;140 mm Hg (standard group; n =1316). After a median follow-up of 3.3 years, the primary composite cardiovascular outcome occurred in 112 intensive group and 131 standard group CKD participants (hazard ratio [HR], 0.81; 95% confidence interval [95% CI], 0.63 to 1.05). The intensive group also had a lower rate of all-cause death (HR, 0.72; 95% CI, 0.53 to 0.99). Treatment effects did not differ between participants with and without CKD ( P values for interactions ≥0.30). The prespecified main kidney outcome, defined as the composite of ≥50% decrease in eGFR from baseline or ESRD, occurred in 15 intensive group and 16 standard group participants (HR, 0.90; 95% CI, 0.44 to 1.83). After the initial 6 months, the intensive group had a slightly higher rate of change in eGFR (−0.47 versus −0.32 ml/min per 1.73 m 2 per year; P &lt;0.03). The overall rate of serious adverse events did not differ between treatment groups, although some specific adverse events occurred more often in the intensive group. Thus, among patients with CKD and hypertension without diabetes, targeting an SBP&lt;120 mm Hg compared with &lt;140 mm Hg reduced rates of major cardiovascular events and all-cause death without evidence of effect modifications by CKD or deleterious effect on the main kidney outcome.